Historical pfe News Stories
Pfizer's Stock Reacts to FDA Approvals and Leadership Changes
Pfizer's stock experiences fluctuations amid FDA approvals and CFO transition.
Pfizer's Stock Performance Amid Recent Developments in the Biopharmaceutical Sector
Analyzing Pfizer's stock fluctuations in light of recent industry events.
Pfizer Q1 Strength Fuels Oncology, Patent Wins Now
Pfizer’s latest quarterly report and corporate moves this week — strong Q1 results, strategic asset sales, patent settlements and ASCO data plans — are reshaping near-term investor expectations for PFE in the S&P 500. Concrete regulatory and pipeline updates reduce risk while dividend payout concerns temper sentiment.
Pfizer PFE: Week Review — No New Catalysts Now Q2!
This week brought no new, stock-moving developments for Pfizer (PFE). Investors should watch the upcoming VESPER-3 obesity readout (June 6, 2026) and the YaoPharma GLP‑1 collaboration (YP05002) as the next meaningful catalysts; near-term trading is likely to be driven by macro, dividend appeal, and positioning within the S&P 500.
Pfizer's $0.43 Dividend & Matrix‑M Deal
Pfizer reinforced shareholder returns with a $0.43 quarterly dividend while striking a strategic license with Novavax for the Matrix‑M adjuvant. These concrete moves — dividend continuity and a deal with explicit financial terms — materially affect PFE’s near‑term investor narrative and long‑term vaccine strategy.
Pfizer Up: PF-3944 Data, BaseLaunch & Guidance Q2.
Pfizer’s recent week brought tangible catalysts: promising PF-3944 obesity data, a BaseLaunch partnership for early-stage access, confirmation of 2026 guidance and an FDA Priority Review for HYMPAVZI. These developments created near-term upside for PFE while setting a clear, pipeline-driven roadmap for 2026.